Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor

A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat

(2016) Ling Han et al.   NEUROREPORT

DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice

(2015) MingJie Ma et al.   Cardiovascular Diabetology

Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke

(2015) Konstantinos Tziomalos et al.   Diabetes & Vascular Disease Research

Glucagon-Like Receptor 1 Agonists and DPP-4 Inhibitors: Potential Therapies for the Treatment of Stroke

(2015) Vladimer Darsalia et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

A review of gliptins for 2014

(2014) André J Scheen   EXPERT OPINION ON PHARMACOTHERAPY

Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy

(2014) Yuliya Sharkovska et al.   JOURNAL OF HYPERTENSION

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors

(2014) Na-Hyung Kim et al.   Biomed Research International

Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice

(2013) Dong Yang et al.   BRAIN RESEARCH

Diabetes drugs and neurological disorders: new views and therapeutic possibilities

(2013) Cesare Patrone et al.   Lancet Diabetes & Endocrinology

Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition

(2012) Swenja Kröller-Schön et al.   CARDIOVASCULAR RESEARCH

The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain: A Comparison With Glimepiride

(2012) V. Darsalia et al.   DIABETES

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

(2010) C. F. Deacon   DIABETES OBESITY & METABOLISM

CXCL12 inhibits expression of the NMDA receptor's NR2B subunit through a histone deacetylase-dependent pathway contributing to neuronal survival

(2010) J Nicolai et al.   Cell Death & Disease

Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats

(2009) Holger Fuchs et al.   BIOPHARMACEUTICS & DRUG DISPOSITION